<ul>
<li><em>BioNTech 已完成收購 CureVac 的交換要約</em></li>
<li><em>此次收購補充了 BioNTech 在 mRNA 設計、遞送配方和 mRNA 生產方面的能力和專有技術</em></li>
<li><em>總計約 86.75% 的 CureVac 股份被提交；BioNTech 預計將在 2026 年 1 月完成對剩餘 CureVac 股份的強制收購，作為之前宣佈的要約後重組的一部分</em></li>
<li><em>CureVac 將繼續在其現有的組織流程下運營，而 BioNTech 將完成所需的戰略、運營和科學分析，以定義未來的組織和投資組合設置</em></li>
</ul>
<p><strong>德國美因茨，2025 年 12 月 18 日</strong>– BioNTech SE（納斯達克：BNTX，“BioNTech” 或 “公司”）今天宣佈已完成對 CureVac N.V.（納斯達克：CVAC，“CureVac”）的收購，並且對所有未償還 CureVac 股份的交換要約的後續要約期（“後續要約期”）於今天凌晨 12:01（東部時間）到期。通過成功收購，BioNTech 打算進一步補充其在 mRNA 設計、遞送配方和 mRNA 生產方面的能力和專有技術。此次收購建立在 BioNTech 在全球 mRNA 行業的良好業績和既定地位之上，並支持公司在腫瘤學戰略的執行，該戰略專注於兩個全腫瘤項目：基於 mRNA 的癌症免疫療法候選藥物，以及與百時美施貴寶公司（紐約證券交易所：BMY，“BMS”）共同開發的雙特異性抗體候選藥物 pumitamig（BNT327/BMS986545），該藥物靶向 PD-L1 和 VEGF-A。</p>
<p>“我想感謝所有幫助使這筆交易成功的人。這深化了我們的 mRNA 技術平台，並提供了擴展我們開發 mRNA 作為新治療藥物類別的潛力，”<strong>BioNTech 首席執行官兼聯合創始人 Ugurs Sahin 教授，醫學博士</strong> 表示。“憑藉一款已獲批准的 mRNA 產品和多個涵蓋不同作用機制的後期項目，我們正在推進新一代藥物，旨在為患者提供實質性益處。”</p>
<p>“通過這次收購，德國早期 mRNA 公司的開創性努力得以結合——願景與技術的協同。兩者都源於德國並非偶然，背後有如 ATHOS KG 和 dievini Hopp BioTech holding 等具有企業精神的長期導向家族辦公室的支持，”<strong>BioNTech 監事會主席 Helmut Jeggle</strong> 表示。“這筆交易具有顯著潛力，有助於推動國家的創新議程，以塑造而不僅僅是跟隨下一波具有全球影響力的創新。”</p>
<p>收購完成後，Ugurs Sahin 教授，醫學博士，Sierk Poetting 博士和 Ramón Zapata-Gomez 將組成 CureVac SE 的管理委員會，CureVac SE 管理委員會的前成員自願辭去職務。CureVac 將保持其現有的組織流程，以確保業務的無縫連續性，而 BioNTech 將完成所需的戰略、運營和科學分析，以定義未來的組織和投資組合設置。</p>
<p>BioNTech 收到交換要約的交換代理 Computershare Trust Company, N.A.的通知，截至後續要約期的到期時間，共有 195,341,219 股 CureVac 股份有效提交，合計約佔 CureVac 已發行和流通股份的 86.75%。公司預計將在 2026 年 1 月完成對剩餘 CureVac 股份的強制收購，作為之前宣佈的要約後重組的一部分。CureVac 股份將在要約後重組後不再可交易。</p>
<p>有關要約的更多信息，包括要約後重組，已在 BioNTech 於 2025 年 11 月 26 日和 2025 年 12 月 3 日發佈的新聞稿中詳細説明。</p>
<p><strong>關於 BioNTech</strong></p>
<p>生物製藥新技術（BioNTech）是一家全球領先的下一代免疫療法公司，開創了針對癌症和其他嚴重疾病的新型研究療法。BioNTech 利用廣泛的計算發現和治療方式，旨在快速開發新型生物製藥。其多樣化的腫瘤產品候選組合旨在解決癌症的全譜系，包括 mRNA 癌症免疫療法、下一代免疫調節劑和靶向療法，如抗體藥物偶聯物（ADCs）和創新的嵌合抗原受體（CAR）T 細胞療法。基於其在 mRNA 開發和內部製造能力方面的深厚專業知識，BioNTech 及其合作伙伴正在研究和開發多種針對一系列傳染病的 mRNA 疫苗候選藥物，同時推進其多樣化的腫瘤管線。BioNTech 已與多家全球和專業製藥合作伙伴建立了廣泛的關係，包括百時美施貴寶、Duality Biologics、復星醫藥、基因泰克（羅氏集團成員）、Genmab、MediLink、OncoC4、輝瑞和再生元。</p>
<p>欲瞭解更多信息，請訪問 www.BioNTech.com。</p>
<p><strong>關於前瞻性聲明的警示聲明</strong></p>
<p>本文件包含 “前瞻性聲明”。前瞻性聲明通常可以通過諸如 “潛在”、“可以”、“將”、“計劃”、“可能”、“能夠”、“會”、“期望”、“期待”、“調查性”、“管道”、“收購”、“開發”、“包括”、“承諾” 或類似術語來識別。這些前瞻性聲明包括但不限於與 2025 年 6 月 12 日 BioNTech 與 CureVac 之間的購買協議（“購買協議”）相關的要約及其他交易的聲明，交易所期望實現的利益，交易後 BioNTech 的潛力和能力，以及交易對 BioNTech 和 CureVac 的潛在影響。這些風險和不確定性中的許多超出了 BioNTech 或 CureVac 的控制範圍。投資者被提醒，任何此類前瞻性聲明均基於 BioNTech 對未來事件的當前信念和期望，並不保證未來的表現，並涉及風險和不確定性。如果基本假設被證明不準確或風險或不確定性實現，實際結果可能與前瞻性聲明中所述的結果有重大差異。您不應對這些聲明過度依賴。</p>
<p>風險和不確定性包括但不限於，購買協議所涉及交易的干擾影響，以及交易對 BioNTech 業務的影響，包括與員工、商業夥伴或政府實體的關係；與交易相關的任何法律程序的結果；由於購買協議所涉及的交易或其他原因，管理層對持續業務運營和機會的注意力分散；一般行業狀況和競爭；一般政治、經濟和商業狀況，包括利率、通貨膨脹、關税和匯率波動，以及持續的俄羅斯 - 烏克蘭和中東衝突；美國、歐洲及歐洲以外國家和地區的監管發展和變化的影響，包括税務事項；美國、歐洲及其他地區製藥行業監管和醫療保健立法的影響；醫生和患者的特定處方偏好；來自其他產品的競爭；新產品開發中固有的挑戰和不確定性；獲得或維持專有知識產權保護的能力；安全、質量、數據完整性或製造問題；以及潛在或實際的數據安全和數據隱私泄露。</p>
<p>BioNTech 不承擔任何義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，法律要求的情況除外。可能導致結果與前瞻性聲明中描述的結果有重大差異的其他因素可以在 BioNTech 截至 2024 年 12 月 31 日的 20-F 表格年度報告中找到，該報告已通過與 SEC 的後續提交進行修訂，相關文件可在 SEC 網站 www.sec.gov 上獲取。</p>
<p><strong>聯繫方式</strong></p>
<p><strong>投資者關係</strong></p>
<p>道格拉斯·馬菲博士</p>
<p>Investors@BioNTech.de</p>
<p><strong>媒體關係</strong></p>
<p>賈斯米娜·阿拉托維奇</p>
<p>Media@BioNTech.de</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png"/></p>

BNTX

CVAC

<p>BioNTech 已完成對 CureVac 的收購，增強了其 mRNA 能力。約 86.75% 的 CureVac 股份已被提交，剩餘股份預計將在 2026 年 1 月前收購。CureVac 將繼續運營，同時 BioNTech 將整合戰略和科學分析。這項收購鞏固了 BioNTech 在 mRNA 領域的地位，並支持其腫瘤學戰略。CureVac 的管理委員會將在收購後重新組成</p>

<ul>
<li><em>BioNTech has completed its exchange offer to acquire CureVac</em></li>
<li><em>Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing</em></li>
<li><em>In total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization</em></li>
<li><em>CureVac will continue to operate under its existing organizational processes, while BioNTech will conclude the strategic, operational, and scientific analyses required to define the future organizational and portfolio setup</em></li>
</ul>
<div class="lb-trans"><ul>
<li><em>BioNTech 已完成收購 CureVac 的交換要約</em></li>
<li><em>此次收購補充了 BioNTech 在 mRNA 設計、遞送配方和 mRNA 生產方面的能力和專有技術</em></li>
<li><em>總計約 86.75% 的 CureVac 股份被提交；BioNTech 預計將在 2026 年 1 月完成對剩餘 CureVac 股份的強制收購，作為之前宣佈的要約後重組的一部分</em></li>
<li><em>CureVac 將繼續在其現有的組織流程下運營，而 BioNTech 將完成所需的戰略、運營和科學分析，以定義未來的組織和投資組合設置</em></li>
</ul>
</div><p><strong>MAINZ, Germany, December 18, 2025</strong>– BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech’s proven track record and established position in the global mRNA industry and supports the execution of the Company’s oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”).</p>
<div class="lb-trans"><p><strong>德國美因茨，2025 年 12 月 18 日</strong>– BioNTech SE（納斯達克：BNTX，“BioNTech” 或 “公司”）今天宣佈已完成對 CureVac N.V.（納斯達克：CVAC，“CureVac”）的收購，並且對所有未償還 CureVac 股份的交換要約的後續要約期（“後續要約期”）於今天凌晨 12:01（東部時間）到期。通過成功收購，BioNTech 打算進一步補充其在 mRNA 設計、遞送配方和 mRNA 生產方面的能力和專有技術。此次收購建立在 BioNTech 在全球 mRNA 行業的良好業績和既定地位之上，並支持公司在腫瘤學戰略的執行，該戰略專注於兩個全腫瘤項目：基於 mRNA 的癌症免疫療法候選藥物，以及與百時美施貴寶公司（紐約證券交易所：BMY，“BMS”）共同開發的雙特異性抗體候選藥物 pumitamig（BNT327/BMS986545），該藥物靶向 PD-L1 和 VEGF-A。</p>
</div><p>“I want to thank everyone who helped make this transaction a success. It deepens our mRNA technology platform and offers potential to expand the ways we can develop mRNA as a new therapeutic drug class,” said <strong>Prof. Ugur Sahin, M.D.,</strong> <strong>CEO and Co-Founder of BioNTech</strong>. “With an approved mRNA product and multiple late-stage programs spanning distinct mechanisms of action, we are advancing a new generation of medicines aimed at delivering meaningful benefits for patients.”</p>
<div class="lb-trans"><p>“我想感謝所有幫助使這筆交易成功的人。這深化了我們的 mRNA 技術平台，並提供了擴展我們開發 mRNA 作為新治療藥物類別的潛力，”<strong>BioNTech 首席執行官兼聯合創始人 Ugurs Sahin 教授，醫學博士</strong> 表示。“憑藉一款已獲批准的 mRNA 產品和多個涵蓋不同作用機制的後期項目，我們正在推進新一代藥物，旨在為患者提供實質性益處。”</p>
</div><p>“With this acquisition, the pioneering efforts of two of Germany’s early mRNA firms are being brought together – a synergy of vision and technology. It is no coincidence that both originated in Germany, backed by dedicated long-term oriented family offices with an entrepreneurial spirit such as ATHOS KG and the dievini Hopp BioTech holding,” said <strong>Helmut Jeggle, Chairman of the BioNTech Supervisory Board</strong>. “This transaction has significant potential to contribute to the country’s innovation agenda to shape, not just follow, the next wave of innovation with global impact.”</p>
<div class="lb-trans"><p>“通過這次收購，德國早期 mRNA 公司的開創性努力得以結合——願景與技術的協同。兩者都源於德國並非偶然，背後有如 ATHOS KG 和 dievini Hopp BioTech holding 等具有企業精神的長期導向家族辦公室的支持，”<strong>BioNTech 監事會主席 Helmut Jeggle</strong> 表示。“這筆交易具有顯著潛力，有助於推動國家的創新議程，以塑造而不僅僅是跟隨下一波具有全球影響力的創新。”</p>
</div><p>Following the closing of the acquisition, Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez will constitute the Management Board of CureVac SE as the former members of the CureVac SE Management Board voluntarily resigned from their positions. CureVac will maintain its existing organizational processes to ensure a seamless continuity of its business, while BioNTech will conclude the strategic, operational and scientific analyses required to define the future organizational and portfolio setup.</p>
<div class="lb-trans"><p>收購完成後，Ugurs Sahin 教授，醫學博士，Sierk Poetting 博士和 Ramón Zapata-Gomez 將組成 CureVac SE 的管理委員會，CureVac SE 管理委員會的前成員自願辭去職務。CureVac 將保持其現有的組織流程，以確保業務的無縫連續性，而 BioNTech 將完成所需的戰略、運營和科學分析，以定義未來的組織和投資組合設置。</p>
</div><p>BioNTech was informed by Computershare Trust Company, N.A., the exchange agent for the Offer, that, as of the expiration time of the Subsequent Offering Period, a total of 195,341,219 CureVac shares, collectively representing approximately 86.75% of CureVac’s issued and outstanding shares, were validly tendered in the Offer. The Company expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization. CureVac shares will no longer be available for trading following the post-offer reorganization.</p>
<div class="lb-trans"><p>BioNTech 收到交換要約的交換代理 Computershare Trust Company, N.A.的通知，截至後續要約期的到期時間，共有 195,341,219 股 CureVac 股份有效提交，合計約佔 CureVac 已發行和流通股份的 86.75%。公司預計將在 2026 年 1 月完成對剩餘 CureVac 股份的強制收購，作為之前宣佈的要約後重組的一部分。CureVac 股份將在要約後重組後不再可交易。</p>
</div><p>Further information on the Offer, including the post-offer reorganization, was previously laid out in BioNTech press releases issued on November 26, 2025 and December 3, 2025.</p>
<div class="lb-trans"><p>有關要約的更多信息，包括要約後重組，已在 BioNTech 於 2025 年 11 月 26 日和 2025 年 12 月 3 日發佈的新聞稿中詳細説明。</p>
</div><p><strong>About BioNTech</strong></p>
<div class="lb-trans"><p><strong>關於 BioNTech</strong></p>
</div><p>Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.</p>
<div class="lb-trans"><p>生物製藥新技術（BioNTech）是一家全球領先的下一代免疫療法公司，開創了針對癌症和其他嚴重疾病的新型研究療法。BioNTech 利用廣泛的計算發現和治療方式，旨在快速開發新型生物製藥。其多樣化的腫瘤產品候選組合旨在解決癌症的全譜系，包括 mRNA 癌症免疫療法、下一代免疫調節劑和靶向療法，如抗體藥物偶聯物（ADCs）和創新的嵌合抗原受體（CAR）T 細胞療法。基於其在 mRNA 開發和內部製造能力方面的深厚專業知識，BioNTech 及其合作伙伴正在研究和開發多種針對一系列傳染病的 mRNA 疫苗候選藥物，同時推進其多樣化的腫瘤管線。BioNTech 已與多家全球和專業製藥合作伙伴建立了廣泛的關係，包括百時美施貴寶、Duality Biologics、復星醫藥、基因泰克（羅氏集團成員）、Genmab、MediLink、OncoC4、輝瑞和再生元。</p>
</div><p>For more information, please visit www.BioNTech.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.BioNTech.com。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示聲明</strong></p>
</div><p>This document includes “forward-looking statements.” Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “look forward,” “investigational,” “pipeline,” “to acquire,” “development,” “to include,” “commitment,” or similar terms. Such forward-looking statements include, but are not limited to, statements relating to the Offer and other transactions contemplated by the purchase agreement, dated June 12, 2025, by and between BioNTech and CureVac (the “Purchase Agreement”), the benefits sought to be achieved in the transactions, the potential and capacity of BioNTech following the transaction, and the potential effects of the transactions on BioNTech and CureVac. Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech’s current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.</p>
<div class="lb-trans"><p>本文件包含 “前瞻性聲明”。前瞻性聲明通常可以通過諸如 “潛在”、“可以”、“將”、“計劃”、“可能”、“能夠”、“會”、“期望”、“期待”、“調查性”、“管道”、“收購”、“開發”、“包括”、“承諾” 或類似術語來識別。這些前瞻性聲明包括但不限於與 2025 年 6 月 12 日 BioNTech 與 CureVac 之間的購買協議（“購買協議”）相關的要約及其他交易的聲明，交易所期望實現的利益，交易後 BioNTech 的潛力和能力，以及交易對 BioNTech 和 CureVac 的潛在影響。這些風險和不確定性中的許多超出了 BioNTech 或 CureVac 的控制範圍。投資者被提醒，任何此類前瞻性聲明均基於 BioNTech 對未來事件的當前信念和期望，並不保證未來的表現，並涉及風險和不確定性。如果基本假設被證明不準確或風險或不確定性實現，實際結果可能與前瞻性聲明中所述的結果有重大差異。您不應對這些聲明過度依賴。</p>
</div><p>Risks and uncertainties include, but are not limited to, the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the transactions on BioNTech’s business, including its relationships with employees, business partners or governmental entities; the outcome of any legal proceedings relating to the transactions; a diversion of management’s attention from ongoing business operations and opportunities as a result of the transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and countries and regions outside of Europe, including with respect to tax matters; the impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere; the particular prescribing preferences of physicians and patients; competition from other products; challenges and uncertainties inherent in new product development; ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; and potential or actual data security and data privacy breaches.</p>
<div class="lb-trans"><p>風險和不確定性包括但不限於，購買協議所涉及交易的干擾影響，以及交易對 BioNTech 業務的影響，包括與員工、商業夥伴或政府實體的關係；與交易相關的任何法律程序的結果；由於購買協議所涉及的交易或其他原因，管理層對持續業務運營和機會的注意力分散；一般行業狀況和競爭；一般政治、經濟和商業狀況，包括利率、通貨膨脹、關税和匯率波動，以及持續的俄羅斯 - 烏克蘭和中東衝突；美國、歐洲及歐洲以外國家和地區的監管發展和變化的影響，包括税務事項；美國、歐洲及其他地區製藥行業監管和醫療保健立法的影響；醫生和患者的特定處方偏好；來自其他產品的競爭；新產品開發中固有的挑戰和不確定性；獲得或維持專有知識產權保護的能力；安全、質量、數據完整性或製造問題；以及潛在或實際的數據安全和數據隱私泄露。</p>
</div><p>BioNTech does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech’s Annual Report on Form 20-F for the year ended December 31, 2024, as amended by any subsequent filings made with the SEC, available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>BioNTech 不承擔任何義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，法律要求的情況除外。可能導致結果與前瞻性聲明中描述的結果有重大差異的其他因素可以在 BioNTech 截至 2024 年 12 月 31 日的 20-F 表格年度報告中找到，該報告已通過與 SEC 的後續提交進行修訂，相關文件可在 SEC 網站 www.sec.gov 上獲取。</p>
</div><p><strong>CONTACTS</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>Douglas Maffei, Ph.D.</p>
<div class="lb-trans"><p>道格拉斯·馬菲博士</p>
</div><p>Investors@BioNTech.de</p>
<div class="lb-trans"><p>Investors@BioNTech.de</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒體關係</strong></p>
</div><p>Jasmina Alatovic</p>
<div class="lb-trans"><p>賈斯米娜·阿拉托維奇</p>
</div><p>Media@BioNTech.de</p>
<div class="lb-trans"><p>Media@BioNTech.de</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBOVFU0TlNNME1ESXlPRFV5TnpJak1qQXdNRGs0TlE9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0NTU4NSM0MDIyODUyNzIjMjAwMDk4NQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png" alt="" original-src="https://ml-eu.globenewswire.com/media/NDkwODEyNTAtNDRiYi00NmNiLTg4MTEtNmJjODcxMzVhY2JiLTEwMTI1NTgtMjAyNS0xMi0xOC1lbg==/tiny/BioNTech-SE.png"/></p>

BioNTech 完成了對 CureVac N.V.的收購，包括後續的要約期，以鞏固其在 mRNA 領域的獨特地位 | BNTX 股票新聞